In this Issue
- VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control
- A Look at the Latest Oregon Psilocybin Services Complaints
- Zuranolone’s MDD Journey Ends
- Tryp Therapeutics Raises $6M to Forward IV Psilocin Candidate
- Psylo and Co. Win $3M Grant to Develop Neuroplastogens
- Other Stories
***
VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue